Search Results

You are looking at 21 - 30 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection

Peter H. Carroll and James L. Mohler

-risk patients is not completely known,” Dr. Carroll stated. A key feature of the updated guidelines is that they provide alternatives to routine biopsy in men with elevated prostate-specific antigen (PSA) levels, such as serum biomarker testing and parametric

Full access

Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy

Rochelle Payne Ondracek, Michael W. Kattan, Christine Murekeyisoni, Changhong Yu, Eric C. Kauffman, James R. Marshall, and James L. Mohler

used to assess failure: (1) NCCN-defined biochemical failure (BF; “failure of prostate-specific antigen [PSA] to fall to undetectable levels,” 17 defined as PSA persistence; or “undetectable PSA after RP with a subsequent detectable PSA that increases

Full access

Association Between Urologist Characteristics and Radiation Oncologist Consultation for Patients With Locoregional Prostate Cancer

Ruben G.W. Quek, Kevin C. Ward, Viraj A. Master, Chun Chieh Lin, Kenneth M. Portier, Katherine S. Virgo, and Joseph Lipscomb

prostate-specific antigen levels at time of diagnosis were recorded in SEER from 2004, and up until 2007, Medicare files used Unique Physician Identification Numbers that are required to link with the AMAPM. epidemiologically significant population

Full access

Update on PSA Testing

Mark L. Gonzalgo and H. Ballentine Carter

-confined prostate cancer is increased through prostate-specific antigen-based screening . JAMA 1993 ; 270 : 948 – 954 . 2. Catalona WJ Richie JP Ahmann FR . Comparison of digital rectal examination and serum prostate specific antigen in the early

Full access

Germline and Somatic Mutations in Prostate Cancer for the Clinician

Heather H. Cheng, Alexandra O. Sokolova, Edward M. Schaeffer, Eric J. Small, and Celestia S. Higano

for men with pathogenic germline mutations associated with increased prostate cancer risk. The ongoing IMPACT study is evaluating the role of targeted prostate-specific antigen (PSA) screening in men with BRCA1/2 mutations ( ClinicalTrials

Full access

Salvage or Adjuvant Radiation Therapy: Counseling Patients on the Benefits

Matthew E. Nielsen, Bruce J. Trock, and Patrick C. Walsh

D espite the stage migration and concomitant improvements in prostate cancer–specific survival (PCSS) associated with widespread prostate-specific antigen (PSA) screening, approximately 1 in 3 men with clinically localized disease will develop a

Full access

Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review

Ghadeer Olleik, Wassim Kassouf, Armen Aprikian, Jason Hu, Marie Vanhuyse, Fabio Cury, Stuart Peacock, Elin Bonnevier, Ebba Palenius, and Alice Dragomir

; AS, active surveillance; MiPS, Mi-Prostate Score; MRTB, MRI-targeted biopsy; PCa, prostate cancer; PCMT, Prostate Core Mitomic Test; PHI, Prostate Health Index; PSA, prostate-specific antigen; Rad Tx, radical treatment; TRUSGB, transrectal ultrasound

Full access

Major Response to Cyclophosphamide and Prednisone in Recurrent Castration-Resistant Prostate Cancer

Nicolas Batty, Naveen Yarlagadda, and Roberto Pili

prednisone. Case Report A 43-year-old man noted urinary frequency and hesitancy, with incomplete voiding. His prostate-specific antigen (PSA) level was 387 ng/mL ( Figure 1 ). A transrectal ultrasound revealed an enlarged prostate gland

Full access

Characterization of Prostate Cancer in a Functional Eunuch

John J. Stocking, Michael V. Fiandalo, Elena A. Pop, John H. Wilton, Gissou Azabdaftari, and James L. Mohler

started testosterone replacement therapy (TRT) to treat hypogonadal symptoms at age 60 years when his prostate examination was benign, prostate-specific antigen (PSA) level was 0.43 mcg/dL ( Table 1 ), and PSA doubling time was 3.18 years. Transrectal

Full access

The Case for Tailored Prostate Cancer Screening: An NCCN Perspective

Michelle L. McDonald and J. Kellogg Parsons

part to lead time bias after earlier detection through widespread use of prostate-specific antigen (PSA) testing, this trend has also largely been attributed to the treatment of screen-detected tumors. 2 – 4 Randomized trials have since confirmed the